Solid forms of a modulator of hemoglobin
Forms of (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyde (Compound I), or salts or solvates thereof, were prepared and characterized in the solid state. Also provided are processes of manufacture and methods of using the forms of Compound I.
1. A crystalline Compound I Form I having the formula:
characterized by an X-ray powder diffractogram comprising diffraction peaks 10.8±0.2, 17.3±0.2, 17.5±0.2, 18.3±0.2, 23.4±0.2, 23.7±0.2, and 26.1±0.2 °2θ, as determined on a diffractometer using Cu-Kα radiation.
2. The crystalline Compound I Form I of claim 1 , wherein the crystalline Compound I Form I is characterized by the X-ray powder diffractogram as substantially shown in FIG. 1 .
3. The crystalline Compound I Form I of claim 1 , wherein the crystalline Compound I Form I is characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 111° C.
4. The crystalline Compound I Form I of claim 1 , wherein the crystalline Compound I Form I is characterized by the DSC curve as substantially shown in FIG. 2 A .
5. The crystalline Compound I Form I of claim 1 , having unit cell parameters: a=5.50599(10) Å, b=16.4086(2) Å, c=20.4992(4) Å, α=90°, β=90°, γ=90°, and volume=1852.02(5) Å 3 .
6. A crystalline Compound I Material II having the formula:
characterized by an X-ray powder diffractogram comprising diffraction peaks 14.9±0.2, 16.7±0.2, 18.4±0.2, 18.6±0.2, 19.2±0.2, 19.6±0.2, 20.2±0.2, 22.9±0.2, and 25.8±0.2 °2θ, as determined on a diffractometer using Cu-Kα radiation.
7. The crystalline Compound I Material II of claim 6 , wherein the crystalline Compound I Material II is characterized by the X-ray powder diffractogram as substantially shown in FIG. 5 .
8. The crystalline Compound I Material II of claim 6 , wherein the crystalline Compound I Material II is characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 102° C.
9. The crystalline Compound I Material II of claim 6 , wherein the crystalline Compound I Material II is characterized by the DSC curve as substantially shown in FIG. 6 .
10. A crystalline Compound I HCl Form A having the formula:
characterized by an X-ray powder diffractogram comprising diffraction peaks 12.7±0.2, 16.4±0.2, 16.7±0.2, 18.5±0.2 and 23.5±0.2 °2θ, as determined on a diffractometer using Cu-Kα radiation.
11. The crystalline Compound I HCl Form A of claim 10 , wherein the crystalline Compound I HCl Form A is characterized by the X-ray powder diffractogram as substantially shown in FIG. 9 .
12. The crystalline Compound I HCl Form A of claim 10 wherein the crystalline Compound I HCl Form A is characterized by a differential scanning calorimetry (DSC) curve that comprises an endotherm at about 193° C.
13. The crystalline Compound I HCl Form A of claim 10 , wherein the crystalline Compound I HCl Form A is characterized by the DSC curve as substantially shown in FIG. 10 .
14. A pharmaceutical composition comprising the crystalline Compound I Form I of claim 1 and a pharmaceutically acceptable excipient.
15. A pharmaceutical composition comprising a pharmaceutically acceptable excipient, the crystalline Compound I Form I of claim 1 , and another therapeutic agent.
16. A method for increasing oxygen affinity of hemoglobin S in a subject in need thereof, comprising administering to the subject the crystalline Compound I Form I of claim 1 .
17. A method for treating a disorder mediated by hemoglobin in a subject in need thereof, comprising administering to the subject the crystalline Compound I Form I of claim 1 .
18. The method of claim 17 , wherein the hemoglobin is sickle hemoglobin.
19. A method for treating sickle cell disease in a subject in need thereof, comprising administering to the subject the crystalline Compound I Form I of claim 1 .